AVEO after the breakout of strong level now retesting.
Aveo recently announced that the Tivozanib drug , in its second analysis, showed an improved survival hazard ratio. This penny stock news prompted the company’s stock to fly over 60% from Monday’s opening bell to Tuesday’s premarket high of $1.10. But just as quickly as it jumped, AVEO pulled back aggressively during the last 30 minutes of trading on September...
Hey guys, sorry I haven't posted in a while! I'm phasing in to the stock market because it's not so technically influenced; I like the fundamental side but not so much fundamentally inclined. Anyways, technical points AVEO will go down and Zacks Rank #4 means SELL! Do not long AVEO until it retests the support! Do your own research. Good luck.
MACD divergence with a drug approval coming at the end of the month and has a potential buyout coming.